Search

Displaying results 3701 - 3710 of 10000 in total
  1. Drug

    Lexibulin

    go.drugbank.com/drugs/DB05147
    Investigational

    CYT997 is an orally available vascular targeting and cytotoxic agent that has proven effective in animal models of a wide range of tumour types including breast, prostate and colon, as well as some leukemias

  2. Drug

    Spaglumic acid

    go.drugbank.com/drugs/DB08835
    Investigational

    Spaglumic acid is the β-aspartyl isoform of N-Acetyl-l-aspartylglutamate (isospaglumic Acid is N-(N-Acetyl-l-α-aspartyl)-l-glutamic acid). … Specifically spaglumic acid is approved in Portugal under the brand name Naabak and in Greece under the brand name Naaxia for use in patients with allergic conjunctivitis.

    Synonyms: N-Acetyl-L-β-aspartyl-L-glutamic acid
  3. Drug

    Bevasiranib

    go.drugbank.com/drugs/DB06642
    Investigational

    Bevasiranib is a small interfering RNA (siRNA) targeting vascular endothelial growth factor A (VEGF-A).

    Categories: Compounds used in a research, industrial, or household setting
  4. Drug

    ATG003

    go.drugbank.com/drugs/DB05069
    Investigational

    ATG003, a novel anti-angiogenic drug candidate and a formulation of mecamylamine, is currently in clinical development for neovascular age-related macular degeneration.

  5. Drug

    Torcetrapib

    go.drugbank.com/drugs/DB06281
    Investigational

    Torcetrapib (CP-529414, Pfizer) was developed to treat hypercholesterolemia but its development was halted in 2006 when phase III studies showed excessive mortality in the treatment group receiving a combination

  6. Drug

    Doxorubicin

    go.drugbank.com/drugs/DB00997
    ApprovedInvestigational

    Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius along side with daunorubicin, another cytotoxic agent, in 1970. … [A257614] Thanks to its efficacy and broad effect, doxorubicin was approved by the FDA in 1974 to treat a variety of cancer, including but not limited to breast, lung, gastric, ovarian, thyroid, non-Hodgkin

  7. Drug

    Altanserin

    go.drugbank.com/drugs/DB19972
    Investigational

    Altanserin is under investigation in clinical trial NCT03970239 (Serotonin in Impulse Control Disorders in Parkinson's Disease). Altanserin has a monoisotopic molecular weight of 411.14 Da. … The usage of the INN stem '-anserin' in the name indicates that Altanserin is a serotonin receptor antagonist.

    Categories: Compounds used in a research, industrial, or household setting
  8. Drug

    Rentiapril

    go.drugbank.com/drugs/DB20567
    Experimental

    The usage of the INN stem '-pril' in the name indicates that Rentiapril is a angiotensin-converting enzyme inhibitor. Rentiapril has a monoisotopic molecular weight of 313.04 Da.

    Categories: Agents Acting on the Renin-Angiotensin System
  9. Drug

    XTL-001

    go.drugbank.com/drugs/DB05405
    Investigational

    XTL001 is an investigational monoclonal antibody (MAb) product developed by XTL Biopharmaceuticals to evaluate the safety profile and antiviral activity of the compound in patients chronically infected

  10. Drug

    Desirudin

    go.drugbank.com/drugs/DB11095
    ApprovedWithdrawn

    It has a protein structure that is similar to that of hirudin, the naturally occurring anticoagulant present in the peripharyngeal glands in the medicinal leech, Hirudo medicinalis. … It is mainly indicated for the prevention of deep vein thrombosis in hip replacement surgery patients.